WeVote
Log In

Bill

Bill

HB 453

AN ACT relating to prescription drugs.

2026 Regular Session Introduced by Patrick Flannery

Kentucky HB 453 addresses prescription drug policy; referred to Banking & Insurance Committee for evaluation of coverage, pricing, or regulatory provisions.

to Banking & Insurance (H)
#actuarialanalysis #drugsandmedicines #education #higher #effectivedates #delayed #healthbenefitplanmandate #insurance #health #localmandate #pharmacists #stateemployeehealthplanmandate #stateemployees
0
WeVote Research Nonpartisan
Bill Summary · HB 453

Legislative bill overview

HB 453 is a Kentucky bill relating to prescription drugs that was recently introduced in the House. The bill has been referred to the Banking & Insurance Committee as of January 29, 2026. Without access to the full bill text, the specific provisions cannot be detailed, but the committee assignment suggests it may address insurance coverage, pricing, or regulatory aspects of pharmaceutical products.

Why is this important

Prescription drug policy affects millions of Kentuckians' access to medications and healthcare costs. Legislation in this area can influence drug pricing transparency, insurance coverage requirements, pharmacy practices, or pharmaceutical regulations—all of which impact both consumers and healthcare providers.

Potential points of contention

  • Pricing and affordability concerns – Any provisions affecting drug costs could face opposition from pharmaceutical manufacturers concerned about profit margins versus advocates seeking lower patient expenses
  • Insurance coverage mandates – Requirements for coverage of specific drugs or classes may create disputes between insurers, employers, and patient advocacy groups
  • Regulatory scope – Questions about whether the state should regulate areas typically under federal FDA jurisdiction or insurance commission authority

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.